疾患修飾性抗リウマチ薬のグローバル市場 2021年：企業別、地域別、種類・用途別

• 英文タイトル：Global Disease-Modifying Antirheumatic Drug Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-203B16135 • 出版社/出版日：GlobalInfoResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

疾患修飾性抗リウマチ薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の疾患修飾性抗リウマチ薬の市場規模は2020年のxxx米ドルから2021年にはxxx米ドルと推定され、2020年から2021年の間にxxx％の変化があります。世界の疾患修飾性抗リウマチ薬の市場規模は次の5年間でxxx％のCAGRで成長すると予想されます。 疾患修飾性抗リウマチ薬市場は種類と用途によって区分されます。2016年～2026年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・非ステロイド性抗炎症薬、ステロイド性抗炎症薬、遅効性薬、免疫学的準備 用途別セグメントは次のように区分されます。 ・製薬産業、病院＆クリニック、その他 世界の疾患修飾性抗リウマチ薬市場の主要な市場プレーヤーは以下のとおりです。 ・AbbVie、Amgen、Pfizer、Roche Holding AG、Novartis International AG、Johnson & Johnson、Bristol-Myers Squibb、Merck、UCB S.A.、Eli Lilly and Company 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計14章あります。 ・第1章では、疾患修飾性抗リウマチ薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な疾患修飾性抗リウマチ薬メーカーの企業概要、2019年～2021年までの疾患修飾性抗リウマチ薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な疾患修飾性抗リウマチ薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2016年～2026年までの地域別疾患修飾性抗リウマチ薬の販売量、売上、成長性を示しています。 ・第5、6章では、2016年～2026年までの疾患修飾性抗リウマチ薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2016年～2021年までの世界の主要国での販売量、売上、市場シェア、並びに2021年～2026年までの主要地域での疾患修飾性抗リウマチ薬市場予測を収録しています。 ・第12、13、14章では、疾患修飾性抗リウマチ薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：AbbVie、Amgen、Pfizer、Roche Holding AG、Novartis International AG、Johnson & Johnson、Bristol-Myers Squibb、Merck、UCB S.A.、Eli Lilly and Company ・メーカー別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：非ステロイド性抗炎症薬、ステロイド性抗炎症薬、遅効性薬、免疫学的準備 ・用途別分析2016年-2026年：製薬産業、病院＆クリニック、その他 ・疾患修飾性抗リウマチ薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・疾患修飾性抗リウマチ薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・疾患修飾性抗リウマチ薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・疾患修飾性抗リウマチ薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・疾患修飾性抗リウマチ薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Disease-Modifying Antirheumatic Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Disease-Modifying Antirheumatic Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Disease-Modifying Antirheumatic Drug market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Disease-Modifying Antirheumatic Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Non-Steroidal Anti-Inflammatory Drugs
Steroidal Anti-Inflammatory Drugs
Slow Acting Drug
Immunological Preparation

Market segment by Application can be divided into
Pharmaceutical Industry
Hospital and Clinic
Other

The key market players for global Disease-Modifying Antirheumatic Drug market are listed below:
AbbVie
Amgen
Pfizer
Roche Holding AG
Novartis International AG
Johnson & Johnson
Bristol-Myers Squibb
Merck
UCB S.A.
Eli Lilly and Company

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Disease-Modifying Antirheumatic Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Disease-Modifying Antirheumatic Drug, with price, sales, revenue and global market share of Disease-Modifying Antirheumatic Drug in 2018 and 2019.
Chapter 3, the Disease-Modifying Antirheumatic Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Disease-Modifying Antirheumatic Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Disease-Modifying Antirheumatic Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Disease-Modifying Antirheumatic Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Disease-Modifying Antirheumatic Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Disease-Modifying Antirheumatic Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Non-Steroidal Anti-Inflammatory Drugs
1.2.3 Steroidal Anti-Inflammatory Drugs
1.2.4 Slow Acting Drug
1.2.5 Immunological Preparation
1.3 Market Analysis by Application
1.3.1 Overview: Global Disease-Modifying Antirheumatic Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Pharmaceutical Industry
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Global Disease-Modifying Antirheumatic Drug Market Size & Forecast
1.4.1 Global Disease-Modifying Antirheumatic Drug Sales in Value (2016-2026))
1.4.2 Global Disease-Modifying Antirheumatic Drug Sales in Volume (2016-2026)
1.4.3 Global Disease-Modifying Antirheumatic Drug Price by Type (2016-2026) & (USD/MT)
1.5 Global Disease-Modifying Antirheumatic Drug Production Capacity Analysis
1.5.1 Global Disease-Modifying Antirheumatic Drug Total Production Capacity (2016-2026)
1.5.2 Global Disease-Modifying Antirheumatic Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Disease-Modifying Antirheumatic Drug Market Drivers
1.6.2 Disease-Modifying Antirheumatic Drug Market Restraints
1.6.3 Disease-Modifying Antirheumatic Drug Trends Analysis
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Disease-Modifying Antirheumatic Drug Product and Services
2.1.4 AbbVie Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Disease-Modifying Antirheumatic Drug Product and Services
2.2.4 Amgen Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Disease-Modifying Antirheumatic Drug Product and Services
2.3.4 Pfizer Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Roche Holding AG
2.4.1 Roche Holding AG Details
2.4.2 Roche Holding AG Major Business
2.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Product and Services
2.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Novartis International AG
2.5.1 Novartis International AG Details
2.5.2 Novartis International AG Major Business
2.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Product and Services
2.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Product and Services
2.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Bristol-Myers Squibb
2.7.1 Bristol-Myers Squibb Details
2.7.2 Bristol-Myers Squibb Major Business
2.7.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product and Services
2.7.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Disease-Modifying Antirheumatic Drug Product and Services
2.8.4 Merck Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 UCB S.A.
2.9.1 UCB S.A. Details
2.9.2 UCB S.A. Major Business
2.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Product and Services
2.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Eli Lilly and Company
2.10.1 Eli Lilly and Company Details
2.10.2 Eli Lilly and Company Major Business
2.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product and Services
2.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Disease-Modifying Antirheumatic Drug Sales by Manufacturer
3.1 Global Disease-Modifying Antirheumatic Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Disease-Modifying Antirheumatic Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Disease-Modifying Antirheumatic Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Disease-Modifying Antirheumatic Drug Manufacturer Market Share
3.4.2 Top 6 Disease-Modifying Antirheumatic Drug Manufacturer Market Share
3.5 Global Disease-Modifying Antirheumatic Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Disease-Modifying Antirheumatic Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Disease-Modifying Antirheumatic Drug Market Size by Region
4.1.1 Global Disease-Modifying Antirheumatic Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Disease-Modifying Antirheumatic Drug Revenue by Region (2016-2026)
4.2 North America Disease-Modifying Antirheumatic Drug Revenue (2016-2026)
4.3 Europe Disease-Modifying Antirheumatic Drug Revenue (2016-2026)
4.4 Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue (2016-2026)
4.5 South America Disease-Modifying Antirheumatic Drug Revenue (2016-2026)
4.6 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Disease-Modifying Antirheumatic Drug Sales in Volume by Type (2016-2026)
5.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2016-2026)
5.3 Global Disease-Modifying Antirheumatic Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Disease-Modifying Antirheumatic Drug Sales in Volume by Application (2016-2026)
6.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2016-2026)
6.3 Global Disease-Modifying Antirheumatic Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Disease-Modifying Antirheumatic Drug Sales by Type (2016-2026)
7.2 North America Disease-Modifying Antirheumatic Drug Sales by Application (2016-2026)
7.3 North America Disease-Modifying Antirheumatic Drug Market Size by Country
7.3.1 North America Disease-Modifying Antirheumatic Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Disease-Modifying Antirheumatic Drug Sales by Type (2016-2026)
8.2 Europe Disease-Modifying Antirheumatic Drug Sales by Application (2016-2026)
8.3 Europe Disease-Modifying Antirheumatic Drug Market Size by Country
8.3.1 Europe Disease-Modifying Antirheumatic Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Disease-Modifying Antirheumatic Drug Market Size by Region
9.3.1 Asia-Pacific Disease-Modifying Antirheumatic Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Disease-Modifying Antirheumatic Drug Sales by Type (2016-2026)
10.2 South America Disease-Modifying Antirheumatic Drug Sales by Application (2016-2026)
10.3 South America Disease-Modifying Antirheumatic Drug Market Size by Country
10.3.1 South America Disease-Modifying Antirheumatic Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Disease-Modifying Antirheumatic Drug Market Size by Country
11.3.1 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Disease-Modifying Antirheumatic Drug Typical Distributors
12.3 Disease-Modifying Antirheumatic Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Disease-Modifying Antirheumatic Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Disease-Modifying Antirheumatic Drug Revenue by Application, (USD Million), 2021-2026
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Disease-Modifying Antirheumatic Drug Product and Services
Table 6. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Amgen Basic Information, Manufacturing Base and Competitors
Table 8. Amgen Major Business
Table 9. Amgen Disease-Modifying Antirheumatic Drug Product and Services
Table 10. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Disease-Modifying Antirheumatic Drug Product and Services
Table 14. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 16. Roche Holding AG Major Business
Table 17. Roche Holding AG Disease-Modifying Antirheumatic Drug Product and Services
Table 18. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Novartis International AG Basic Information, Manufacturing Base and Competitors
Table 20. Novartis International AG Major Business
Table 21. Novartis International AG Disease-Modifying Antirheumatic Drug Product and Services
Table 22. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 24. Johnson & Johnson Major Business
Table 25. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product and Services
Table 26. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 28. Bristol-Myers Squibb Major Business
Table 29. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product and Services
Table 30. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Merck Basic Information, Manufacturing Base and Competitors
Table 32. Merck Major Business
Table 33. Merck Disease-Modifying Antirheumatic Drug Product and Services
Table 34. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. UCB S.A. Basic Information, Manufacturing Base and Competitors
Table 36. UCB S.A. Major Business
Table 37. UCB S.A. Disease-Modifying Antirheumatic Drug Product and Services
Table 38. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 40. Eli Lilly and Company Major Business
Table 41. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product and Services
Table 42. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Disease-Modifying Antirheumatic Drug Sales by Manufacturer (2019-2021e) & (MT)
Table 44. Global Disease-Modifying Antirheumatic Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Disease-Modifying Antirheumatic Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Disease-Modifying Antirheumatic Drug Production Capacity by Company, (MT): 2020 VS 2021
Table 47. Head Office and Disease-Modifying Antirheumatic Drug Production Site of Key Manufacturer
Table 48. Disease-Modifying Antirheumatic Drug New Entrant and Capacity Expansion Plans
Table 49. Disease-Modifying Antirheumatic Drug Mergers & Acquisitions in the Past Five Years
Table 50. Global Disease-Modifying Antirheumatic Drug Sales by Region (2016-2021e) & (MT)
Table 51. Global Disease-Modifying Antirheumatic Drug Sales by Region (2021-2026) & (MT)
Table 52. Global Disease-Modifying Antirheumatic Drug Revenue by Region (2016-2021e) & (USD Million)
Table 53. Global Disease-Modifying Antirheumatic Drug Revenue by Region (2021-2026) & (USD Million)
Table 54. Global Disease-Modifying Antirheumatic Drug Sales by Type (2016-2021e) & (MT)
Table 55. Global Disease-Modifying Antirheumatic Drug Sales by Type (2021-2026) & (MT)
Table 56. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2016-2021e) & (USD Million)
Table 57. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2021-2026) & (USD Million)
Table 58. Global Disease-Modifying Antirheumatic Drug Price by Type (2016-2021e) & (USD/MT)
Table 59. Global Disease-Modifying Antirheumatic Drug Price by Type (2021-2026) & (USD/MT)
Table 60. Global Disease-Modifying Antirheumatic Drug Sales by Application (2016-2021e) & (MT)
Table 61. Global Disease-Modifying Antirheumatic Drug Sales by Application (2021-2026) & (MT)
Table 62. Global Disease-Modifying Antirheumatic Drug Revenue by Application (2016-2021e) & (USD Million)
Table 63. Global Disease-Modifying Antirheumatic Drug Revenue by Application (2021-2026) & (USD Million)
Table 64. Global Disease-Modifying Antirheumatic Drug Price by Application (2016-2021e) & (USD/MT)
Table 65. Global Disease-Modifying Antirheumatic Drug Price by Application (2021-2026) & (USD/MT)
Table 66. North America Disease-Modifying Antirheumatic Drug Sales by Country (2016-2021e) & (MT)
Table 67. North America Disease-Modifying Antirheumatic Drug Sales by Country (2021-2026) & (MT)
Table 68. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2021e) & (USD Million)
Table 69. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2021-2026) & (USD Million)
Table 70. North America Disease-Modifying Antirheumatic Drug Sales by Type (2016-2021e) & (MT)
Table 71. North America Disease-Modifying Antirheumatic Drug Sales by Type (2021-2026) & (MT)
Table 72. North America Disease-Modifying Antirheumatic Drug Sales by Application (2016-2021e) & (MT)
Table 73. North America Disease-Modifying Antirheumatic Drug Sales by Application (2021-2026) & (MT)
Table 74. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2016-2021e) & (MT)
Table 75. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2021-2026) & (MT)
Table 76. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2021e) & (USD Million)
Table 77. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2021-2026) & (USD Million)
Table 78. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2016-2021e) & (MT)
Table 79. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2021-2026) & (MT)
Table 80. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2016-2021e) & (MT)
Table 81. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2021-2026) & (MT)
Table 82. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2016-2021e) & (MT)
Table 83. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2021-2026) & (MT)
Table 84. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2016-2021e) & (USD Million)
Table 85. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2021-2026) & (USD Million)
Table 86. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2016-2021e) & (MT)
Table 87. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2021-2026) & (MT)
Table 88. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2016-2021e) & (MT)
Table 89. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2021-2026) & (MT)
Table 90. South America Disease-Modifying Antirheumatic Drug Sales by Country (2016-2021e) & (MT)
Table 91. South America Disease-Modifying Antirheumatic Drug Sales by Country (2021-2026) & (MT)
Table 92. South America Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2021e) & (USD Million)
Table 93. South America Disease-Modifying Antirheumatic Drug Revenue by Country (2021-2026) & (USD Million)
Table 94. South America Disease-Modifying Antirheumatic Drug Sales by Type (2016-2021e) & (MT)
Table 95. South America Disease-Modifying Antirheumatic Drug Sales by Type (2021-2026) & (MT)
Table 96. South America Disease-Modifying Antirheumatic Drug Sales by Application (2016-2021e) & (MT)
Table 97. South America Disease-Modifying Antirheumatic Drug Sales by Application (2021-2026) & (MT)
Table 98. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2016-2021e) & (MT)
Table 99. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2021-2026) & (MT)
Table 100. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2016-2021e) & (USD Million)
Table 101. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type (2016-2021e) & (MT)
Table 103. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type (2021-2026) & (MT)
Table 104. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application (2016-2021e) & (MT)
Table 105. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application (2021-2026) & (MT)
Table 106. Direct Channel Pros & Cons
Table 107. Indirect Channel Pros & Cons
Table 108. Disease-Modifying Antirheumatic Drug Typical Distributors
Table 109. Disease-Modifying Antirheumatic Drug Typical Customers
List of Figures
Figure 1. Disease-Modifying Antirheumatic Drug Picture
Figure 2. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2020
Figure 3. Non-Steroidal Anti-Inflammatory Drugs
Figure 4. Steroidal Anti-Inflammatory Drugs
Figure 5. Slow Acting Drug
Figure 6. Immunological Preparation
Figure 7. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2020
Figure 8. Pharmaceutical Industry
Figure 9. Hospital and Clinic
Figure 10. Other
Figure 11. Global Disease-Modifying Antirheumatic Drug Market Size, (USD Million) & (MT): 2020 VS 2021 VS 2026
Figure 12. Global Disease-Modifying Antirheumatic Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. Global Disease-Modifying Antirheumatic Drug Sales (2016-2026) & (MT)
Figure 14. Global Disease-Modifying Antirheumatic Drug Price by Type (2016-2026) & (USD/MT)
Figure 15. Global Disease-Modifying Antirheumatic Drug Production Capacity (2016-2026) & (MT)
Figure 16. Global Disease-Modifying Antirheumatic Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 17. Disease-Modifying Antirheumatic Drug Market Drivers
Figure 18. Disease-Modifying Antirheumatic Drug Market Restraints
Figure 19. Disease-Modifying Antirheumatic Drug Market Trends
Figure 20. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturer in 2020
Figure 21. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Manufacturer in 2020
Figure 22. Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. Top 3 Disease-Modifying Antirheumatic Drug Manufacturer (Revenue) Market Share in 2020
Figure 24. Top 6 Disease-Modifying Antirheumatic Drug Manufacturer (Revenue) Market Share in 2020
Figure 25. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2016-2026)
Figure 26. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2016-2026)
Figure 27. North America Disease-Modifying Antirheumatic Drug Revenue (2016-2026) & (USD Million)
Figure 28. Europe Disease-Modifying Antirheumatic Drug Revenue (2016-2026) & (USD Million)
Figure 29. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue (2016-2026) & (USD Million)
Figure 30. South America Disease-Modifying Antirheumatic Drug Revenue (2016-2026) & (USD Million)
Figure 31. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue (2016-2026) & (USD Million)
Figure 32. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2016-2026)
Figure 33. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2016-2026)
Figure 34. Global Disease-Modifying Antirheumatic Drug Price by Type (2016-2026) & (USD/MT)
Figure 35. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2016-2026)
Figure 36. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2016-2026)
Figure 37. Global Disease-Modifying Antirheumatic Drug Price by Application (2016-2026) & (USD/MT)
Figure 38. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2016-2026)
Figure 39. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2016-2026)
Figure 40. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2016-2026)
Figure 41. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2016-2026)
Figure 42. United States Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2016-2026)
Figure 46. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2016-2026)
Figure 47. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2016-2026)
Figure 48. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2016-2026)
Figure 49. Germany Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2016-2026)
Figure 58. China Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Korea Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2016-2026)
Figure 65. South America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2016-2026)
Figure 66. South America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2016-2026)
Figure 67. South America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2016-2026)
Figure 71. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Egypt Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. South Africa Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source

---